Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

793
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
793
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

472
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

717
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
717
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

714
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
714
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

660
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
660
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

27
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
27

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Aspirin Discontinuation Postacute Coronary Syndrome: A New Approach to Postmyocardial Infarction Management.

Cardiology in review·2026
Same author

Long-Term Oxygen Therapy and Cardiovascular Physiology: Divergent Effects in Heart Failure and Pulmonary Hypertension.

Cardiology in review·2026
Same author

Assessment of Macular Thickness in Myopic Patients and Its Correlation with Axial Length: A Hospital-Based Study.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Anticoagulation in Atrial Fibrillation and Dementia.

Cardiology in review·2025
Same author

Cardiac Effects in Children of Hypertensive Mothers: A Literature Review.

Cardiology in review·2025
Same author

Protective effects of long term antiplatelet and anticoagulant therapy in hospitalized patients with inflammatory bowel disease.

World journal of gastrointestinal pharmacology and therapeutics·2024

Related Experiment Video

Updated: Jul 29, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Losartan-Induced Angioedema: A Case Report.

Henry Mann1, Sagar Pandey1, Sindhu Pokhriyal1

  • 1Internal Medicine, One Brooklyn Health System, Interfaith Medical Center, New York City, USA.

Cureus
|May 22, 2023
PubMed
Summary
This summary is machine-generated.

Angiotensin receptor blockers (ARBs) can cause angioedema, a rare but serious side effect. This case highlights a severe instance of losartan-induced angioedema, emphasizing the need for awareness.

Keywords:
angioedemaarbdrug-induced angioedemalosartanlosartan induced angioedema

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

37.7K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.9K

Related Experiment Videos

Last Updated: Jul 29, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

37.7K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are known to cause angioedema.
  • Angiotensin receptor blockers (ARBs) are widely used for hypertension, heart failure, and kidney disease.
  • The incidence and severity of ARB-induced angioedema remain less understood compared to ACE inhibitors.

Observation:

  • A case of a 48-year-old African American male experiencing severe angioedema after initiating losartan.
  • The angioedema necessitated a tracheostomy for airway management.
  • This represents one of only twenty reported cases of losartan-induced angioedema in the literature.

Findings:

  • Losartan, an ARB, can precipitate life-threatening angioedema.
  • Prompt medical intervention, including airway support, is crucial in managing severe ARB-induced angioedema.
  • Despite short-term recovery, the patient experienced a fatal cardiac arrest months later, suggesting potential long-term implications.

Implications:

  • Clinicians should maintain a high index of suspicion for angioedema in patients taking ARBs, including losartan.
  • Further research is needed to elucidate the mechanisms and long-term outcomes of ARB-induced angioedema.
  • This case underscores the importance of comprehensive patient monitoring following ARB initiation.